Related references
Note: Only part of the references are listed.Mutations Associated with Reduced Surotomycin Susceptibility in Clostridium difficile and Enterococcus Species
Hannah M. Adams et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile
Mohammed Zahidul Alam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Effects of Surotomycin on Clostridium difficile Viability and Toxin Production In Vitro
Laurent Bouillaut et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Practice Parameters for the Management of Clostridium difficile Infection
Scott R. Steele et al.
DISEASES OF THE COLON & RECTUM (2015)
Spore Cortex Hydrolysis Precedes Dipicolinic Acid Release during Clostridium difficile Spore Germination
Michael B. Francis et al.
JOURNAL OF BACTERIOLOGY (2015)
Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea
Ning Yin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Angie M. Jarrad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Surotomycin Demonstrates Low In Vitro Frequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium
Carmela T. M. Mascio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection
C. H. Chilton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
Christina M. Surawicz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB
Jordi M. Lanis et al.
PLOS PATHOGENS (2013)
Inactivation of the Lipopeptide Antibiotic Daptomycin by Hydrolytic Mechanisms
Vanessa M. D'Costa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species
Diane M. Citron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens
D. R. Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro and In Vivo Characterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile
Carmela T. M. Mascio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
Derrick W. Crook et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
Scott G. Franzblau et al.
TUBERCULOSIS (2012)
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections
Julian G. Hurdle et al.
NATURE REVIEWS MICROBIOLOGY (2011)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD
Barry I. Eisenstein et al.
CLINICAL INFECTIOUS DISEASES (2010)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Stuart H. Cohen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production
Michelle Merrigan et al.
JOURNAL OF BACTERIOLOGY (2010)
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Stuart Johnson
JOURNAL OF INFECTION (2009)
Clostridium difficile-associated disease:: New challenges from an established pathogen
RH Sunenshine et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2006)
Alternative treatments for Clostridium difficile disease:: what really works?
LV Mcfarland
JOURNAL OF MEDICAL MICROBIOLOGY (2005)
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
BH Dvorchik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)